viewGenedrive PLC

Genedrive PLC - Notice of Results

RNS Number : 5633L
Genedrive PLC
09 September 2019


genedrive plc

("genedrive" or the "Company")


Notice of Results


genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its preliminary results for the year ended 30 June 2019 on Thursday, 3 October 2019.


For further details please contact:


genedrive plc


David Budd: CEO / Matthew Fowler: CFO

+44 (0)161 989 0245

Peel Hunt LLP

+44 (0)20 7418 8900

James Steel / Oliver Jackson

Stanford Capital Partners Limited

+44 (0)20 3815 8880

Patrick Claridge / John Howes

Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001


Notes to Editors


About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID kit has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. The Company has assays on market for the detection of certain biological targets and has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).


Further details can be found at: www.genedriveplc.com and www.genedrive.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Genedrive PLC

Price: 95.9

Market: AIM
Market Cap: £49.05 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Genedrive's David Budd details launch of its unique coronavirus test kits...

Genedrive PLC's (LON:GDR) David Budd recaps on its two coronavirus test kits. The first, which was CE marked last week and they're in the process of launching, is a high-throughput lab-based PCR test which assesses whether someone's got an active infection. The second is a point-of-care version...

on 29/5/20